Last updated: 2026-09-16 13:20:40. Prices reflect the latest pre-market trading data. Stock price data is sourced from Massive.
Madrigal Pharmaceuticals, Inc. (MDGL) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $522.43, with a market capitalisation of $12.48B and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $393.61 to $615.00. This page covers its latest market performance, valuation, price trends and company information.
$12.48B | |
$539.25 | |
$615.00 | |
$6.60 | |
$540.06 | |
217.84K | |
344.94K | |
-- | |
$615.00 | |
$393.61 | |
-- | |
-- |
Madrigal Pharmaceuticals, Inc. (MDGL) is trading at $540.20 in pre-market trading as of 2026-09-15 23:31:00, up 0.03% ($0.14) from the previous close of $540.06
Pre-market trading shows how investors are pricing MDGL before the regular session opens. The current pre-market price is near the previous close, indicating positive early trading sentiment.
Over the past seven days, Madrigal Pharmaceuticals, Inc. (MDGL) moved from $541.08 to $522.43, representing a decline of 3.45% ($18.66).
The stock traded between $513.08 and $549.97 during the period. The latest price is near the lower end of the 7-day range, indicating moderate downward.
The average daily volume was 212.46 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 58.2%
MDGL is currently trading at $522.43, placing it 58.2% of the way from its 52-week low of $393.61 to its 52-week high of $615.00. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 915 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Madrigal Pharmaceuticals, Inc. (MDGL) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.